Title : Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.

Pub. Date : 2010 May 4

PMID : 20337484






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 c-Abl and b-Raf are major targets of marketed oncology drugs Imatinib (Gleevec) and Sorafenib (Nexavar), respectively, and BIRB-796 is a p38alpha inhibitor that reached Phase II clinical trials. Sorafenib B-Raf proto-oncogene, serine/threonine kinase Homo sapiens
2 c-Abl and b-Raf are major targets of marketed oncology drugs Imatinib (Gleevec) and Sorafenib (Nexavar), respectively, and BIRB-796 is a p38alpha inhibitor that reached Phase II clinical trials. Sorafenib B-Raf proto-oncogene, serine/threonine kinase Homo sapiens